Engager Bio Overview
- Year Founded
-
2025
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$410K
- Investors
-
1
Engager Bio General Information
Description
Developer of cancer immunotherapies designed to target and eliminate tumor cells through gamma delta T-cell-based treatments. The company develops next-generation oncology therapeutics aimed at improving the effectiveness of cancer treatment while maintaining a favorable safety profile, enabling healthcare providers to address a range of malignant diseases.
Contact Information
Corporate Office
- Amsterdam
- Netherlands
Corporate Office
- Amsterdam
- Netherlands
Engager Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jan-2026 | $410K | Completed | Startup |
Engager Bio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovatiefonds Noord-Holland | Venture Capital | Minority |
Engager Bio FAQs
-
When was Engager Bio founded?
Engager Bio was founded in 2025.
-
Where is Engager Bio headquartered?
Engager Bio is headquartered in Amsterdam, Netherlands.
-
What industry is Engager Bio in?
Engager Bio’s primary industry is Drug Discovery.
-
Is Engager Bio a private or public company?
Engager Bio is a Private company.
-
What is Engager Bio’s current revenue?
The current revenue for Engager Bio is .
-
How much funding has Engager Bio raised over time?
Engager Bio has raised $410K.
-
Who are Engager Bio’s investors?
Innovatiefonds Noord-Holland has invested in Engager Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process